Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_assertion type Assertion NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_head.
- NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_assertion description "[We used the allelic discrimination method to identify polymorphisms in GSTT1, SULT1C2, CDA, SXR (drug metabolic pathways), XPD, XPA, XPG, ERCC1, TOP2A (DNA repair), VEGF (angiogenesis), and MDR1 (multidrug resistance) genes in 110 adult patients with intermediate-risk AML, enrolled in the CETLAM-99 prospective trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_provenance.
- NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_assertion evidence source_evidence_literature NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_provenance.
- NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_assertion SIO_000772 16507781 NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_provenance.
- NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_assertion wasDerivedFrom gad-20150221 NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_provenance.
- NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_assertion wasGeneratedBy ECO_0000203 NP82929.RAfTqI9cJRnN9iVFYh521mjXu3blQqba50Iu20cDbrrC8130_provenance.